Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population

  • At the annual congress of the Muscular Dystrophy Association (MDA), Roche Holdings AG (OTC:RHHBYannounced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam).
  • Evrysdi is a novel survival motor neuron 2 (SMN2) splicing modifier, licensed from PTC Therapeutics Inc (NASDAQ:PTCT).
  • At the annual MDA event, Roche’s presentations included new three-year data from the SUNFISH study, which further confirmed the long-term efficacy and safety of Evrysdi in a broad population of people aged 2-25 years with Type 2 or Type 3 SMA. 
  • Related: Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients.
  • There was also exploratory two-year efficacy data from SUNFISH Part 2, demonstrating improvement in or stabilization of motor function with Evrysdi compared to an untreated external control group. 
  • In addition, Roche revealed updated interim data from the RAINBOWFISH study in pre-symptomatic babies with SMA under two months of age.
  • Price Action: RHHBY shares are down 1.02% at $47.36 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.